Back to Search
ELIZABETH KOHN, MD
MD
Family Medicine Physician
NPI: 1518948165IndividualAccepts Medicare
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
3790(AK)39495(MN)MD00034290(WA)
CMS Specialties
PrimaryFAMILY PRACTICE
Education
UNIVERSITY OF MINNESOTA, DULUTH SCHOOL OF MEDICINE
Class of 1993
Research & Publications (20)
A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
PMID 11410496·Clin Cancer Res·2001
3-trial
Ras activation contributes to the maintenance and expansion of Sca-1pos cells in a mouse model of breast cancer.
PMID 19586713·Cancer Lett·2010
7-preclinical
Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo.
PMID 19154415·Cancer Sci·2009
7-preclinical
Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
PMID 19228742·Clin Cancer Res·2009
8-other
Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma.
PMID 19620938·Int J Gynecol Pathol·2009
8-other
The anti-apoptotic activity of BAG3 is restricted by caspases and the proteasome.
PMID 19352495·PLoS One·2009
8-other
Genomic and phenotypic analysis reveals a key role for CCN1 (CYR61) in BAG3-modulated adhesion and invasion.
PMID 19402132·J Pathol·2009
8-other
BAT3 and SET1A form a complex with CTCFL/BORIS to modulate H3K4 histone dimethylation and gene expression.
PMID 18765639·Mol Cell Biol·2008
7-preclinical
Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
PMID 18300236·Cancer·2008
3-trial
Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia.
PMID 17924401·J Cell Physiol·2008
8-other
Banking of biological fluids for studies of disease-associated protein biomarkers.
PMID 18676364·Mol Cell Proteomics·2008
6-review
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
PMID 18669456·J Clin Oncol·2008
3-trial
Rationale for combination use of targeted agents in ovarian cancer: do we have one?
PMID 18623195·Cancer·2008
8-other
Unlocking diamond's potential as an electronic material.
PMID 18024362·Philos Trans A Math Phys Eng Sci·2008
8-other
Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers.
PMID 18187810·Mol Cancer Ther·2008
8-other
Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines.
PMID 18852115·Mol Cancer Ther·2008
8-other
An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments.
PMID 18483268·Cancer Res·2008
7-preclinical
Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency.
PMID 18464258·Int J Cancer·2008
4-observational
The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells.
PMID 17916899·Carcinogenesis·2008
8-other
Constitution and quantity of lysis buffer alters outcome of reverse phase protein microarrays.
PMID 17952872·Proteomics·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 3 locations total
- Address
- 115 10TH AVE NE STE A, ESSENTIA HEALTH DEER RIVER CLINIC
DEER RIVER, MN 56636 - Phone
- (218) 246-8275
Quick Facts
- NPI
- 1518948165
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 3
- Years in Practice
- 33
- Publications
- 20
Are you this provider?
Claim Your Profile